Nusinersen received FDA approval in December 2016 and is used in the treatment of infants and children diagnosed with Spinal Muscular Atrophy (SMA). This treatment aims to alleviate the symptoms of the disease, thereby improving the quality of life for patients. The decision to administer Nusinersen is individualized based on the patient's clinical condition.